Radiopharmaceutical preparation of a monoclonal antibody, Lym-1, and its F(ab')2 fragment for imaging lymphoma with In-111

S. L. Mills, S. J. De Nardo, Gerald L Denardo, S. V. Deshpande, M. McCall, C. Meares, A. L. Epstein

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

(S)-4-[2,3 bis[bis(carboxymethylamino)propyl]phenyl isothio-cyanate (CITC) was used to attach In-111 to an intact monoclonal antibody (Lym-1) or its fragment F(ab')2 to produce two new radiopharmaceuticals. Immunoreactivity of the Lym-1, specific for B cell lymphoma, was not affected by the coupling reaction for 1.0 and 4.3 CITC molecules per whole antibody and 3.0 CITC molecules per F(ab')2 fragment. Both retained in excess of 90% immunoreactivity even at the level of 25 mCi of In-111 per mg of Lym-1 and 15 mCi per mg F(Ab')2. The labeling reaction produced yields in excess of 98% eliminating the requirement for routine purification of the final radiopharmaceutical.

Original languageEnglish (US)
Pages (from-to)377-386
Number of pages10
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Volume27
Issue number4
StatePublished - 1989

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Medicine
  • Analytical Chemistry
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Radiopharmaceutical preparation of a monoclonal antibody, Lym-1, and its F(ab')<sub>2</sub> fragment for imaging lymphoma with In-111'. Together they form a unique fingerprint.

  • Cite this